Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204410 · ClinicalTrials.gov registry record · Phase 4
Omega-3 Supplementation to ADHD Medication in Children
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02204410: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT02204410 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02204410, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children and adolescents with Attention Deficit/Hyperactivity Disorder. Subjects will be between the ages of 6-17 and will currently be on medication for their Attention Deficit/Hyperactivity Disorder but still experience DESR traits.
Interventions
- DIETARY_SUPPLEMENT Omega-3 Fatty Acid
- DRUG ADHD Medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02204410
The ClinicalTrials.gov registry entry for NCT02204410 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Omega-3 Fatty Acid is the first listed.
NCT02204410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02204410 about?
NCT02204410 is a clinical study titled "Omega-3 Supplementation to ADHD Medication in Children". This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children and adolescents with Attention Deficit/Hyperactivity Disorder. Subjects ...
What is the current status of trial NCT02204410?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2014-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02204410?
The interventions under investigation include: Omega-3 Fatty Acid (DIETARY_SUPPLEMENT), ADHD Medication (DRUG).
Who is sponsoring clinical trial NCT02204410?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.